Next-Generation Biomanufacturing Market - Global Forecast 2025-2032

The next-generation biomanufacturing market is undergoing significant transformation, driven by the adoption of agile, integrated manufacturing solutions. Senior executives emphasize operational flexibility, digital advancement, and strategic alliances to remain competitive and meet the industry’s evolving technical demands.

Market Snapshot: Next-Generation Biomanufacturing Market

In 2024, the global next-generation biomanufacturing market is valued at USD 20.69 billion and is projected to reach USD 22.66 billion by 2025, reflecting a compound annual growth rate of 9.38%. This expansion is fueled by the increasing global need for advanced therapies and vaccines. Organizations are accelerating technology adoption to accommodate clinical and regulatory shifts, supporting extensive digital integration, supply chain resilience, and cross-border partnerships. Collectively, these drivers ensure ongoing access to high-quality therapeutic solutions for the global healthcare market.

Scope & Segmentation of the Next-Generation Biomanufacturing Market

This analysis presents segmentation and insights to guide informed decision making across the biomanufacturing continuum. Each area reveals adoption trends that influence sector development and competitive positioning.

• Product Types: Includes cell and gene therapies, CAR-T, gene-editing platforms, monoclonal antibodies, recombinant proteins, enzymes, mRNA technologies, and multiple vaccine modalities (live attenuated, subunit, viral vector-based).
• Technologies: Encompasses continuous bioprocessing, single-use bioreactors, modular integration, cell-free systems, and real-time analytics to ensure responsive quality management.
• Process Stages: Covers upstream (media prep, bioreactor management) and downstream (purification, product finishing) operations to ensure workflow continuity and product uniformity.
• End Users: Engages academic institutions, contract manufacturers, biotechs, and pharma organizations, highlighting the range from discovery to commercialization.
• Operation Scale: Considers early research, clinical production, and large-scale manufacturing to support tailored solutions for varying organizational needs.
• Cell Lines: Assesses CHO, E. coli, and yeast-based expression systems for producing biotherapeutics and enzymes across diverse industrial sectors.
• Process Modes: Describes batch, fed-batch, continuous, and perfusion methodologies to enable customized process engineering and increased throughput.
• Regions: Analyzes key geographies, covering Americas, Europe, Middle East & Africa, and Asia-Pacific, with particular attention to leading markets such as the United States, Germany, China, Brazil, and India. Regional insights clarify both supply chain strengths and emerging opportunities.
• Key Companies: Profiles organizations like Novozymes A/S, Koninklijke DSM N.V., Evonik Industries AG, Ginkgo Bioworks Holdings Inc., Amyris Inc., Codexis Inc., Zymergen Inc., Genomatica Inc., Evolva Holding SA, and LanzaTech Inc., each contributing to ongoing sector innovation and differentiation.

Key Takeaways for Senior Executives

• Adopting modular and advanced manufacturing approaches increases operational versatility and prepares organizations for changing therapy types and regulatory landscapes.
• Single-use and cell-free platforms help minimize contamination, reduce downtime, and improve quality, enabling faster adaptation to new therapeutic trends.
• Collaboration with technology providers sustains innovation and strengthens investments in robust, scalable manufacturing infrastructure.
• Utilizing digital twins and real-time analytics throughout production increases supply chain transparency and supports data-driven operational efficiency and quality assurance.
• Evaluating local infrastructure and diverse regulatory environments is essential for efficient market entry, resource allocation, and long-term expansion strategies.
• Encouraging technical upskilling and workforce training facilitates successful technology integration and supports competitive positioning as biomanufacturing evolves.

Tariff Impact on Biomanufacturing Supply Chains

Recent U.S. tariffs affecting biomanufacturing equipment and inputs have prompted companies to reassess procurement and supply strategies. Modular production systems, supplier diversification, and regional partnerships are increasingly prioritized. These approaches help maintain continuity and adaptability amid ongoing tariff changes and trade policy developments.

Methodology & Data Sources

This report draws on executive interviews, feedback from operational and R&D leaders, comprehensive literature reviews, and evaluations by industry experts. The methodology combines firsthand market intelligence with independent validation, supporting strategic recommendations for senior stakeholders.

Why This Report Matters

• Enables decision-makers to identify high-impact investments in biomanufacturing technology and strengthen collaborative partnerships for sustained market relevance.
• Delivers segmented views by region and operational scale, facilitating informed site selection, streamlined market expansion, and proactive compliance planning.
• Offers strategic insights to enhance supply chain resilience and resource strategies for effective compliance in changing commercial environments.

Conclusion

Industry leaders who emphasize innovation, ongoing collaboration, and agile operations will maintain their positions as the market evolves. Sustained investment in people, technology, and partnerships is critical for long-term relevance in next-generation biomanufacturing.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.